RESULTS

• 50 patients were enrolled, 17/50 (34%) switching to raltegravir (RAL); 33/50 (66%) to dolutegravir (DTG) -containing 2DR (table 1).

• Upon switch to 2DR, CD4 modestly increased (p=0.038, Table 2), sCD4 significantly decreased (p<0.0001, Table 2), while no changes in CD8, CD4/CD8 ratio, HIV-RNA and HIV-DNA, and other pro-inflammatory markers were observed (Table 2).

• The changes in sCD4 were more relevant in patients switching to DTG vs RAL-containing 2DR (p interaction p=0.014, Table 3).

• No correlations between inflammatory markers and viro-immunological parameters were found.